Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I and Jemal A: Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 74:229–263. 2024. View Article : Google Scholar : PubMed/NCBI

Siegel RL, Giaquinto AN and Jemal A: Cancer statistics, 2024. CA Cancer J Clin. 74:12–49. 2024. View Article : Google Scholar : PubMed/NCBI

Zi H, Liu MY, Luo LS, Huang Q, Luo PC, Luan HH, Huang J, Wang DQ, Wang YB, Zhang YY, et al: Global burden of benign prostatic hyperplasia, urinary tract infections, urolithiasis, bladder cancer, kidney cancer, and prostate cancer from 1990 to 2021. Mil Med Res. 11:642024.PubMed/NCBI

Tian YQ, Yang JC, Hu JJ, Ding R, Ye DW and Shang JW: Trends and risk factors of global incidence, mortality, and disability of genitourinary cancers from 1990 to 2019: Systematic analysis for the global burden of disease study 2019. Front Public Health. 11:11193742023. View Article : Google Scholar : PubMed/NCBI

Chen JQ, Salas LA, Wiencke JK, Koestler DC, Molinaro AM, Andrew AS, Seigne JD, Karagas MR, Kelsey KT and Christensen BC: Immune profiles and DNA methylation alterations related with non-muscle-invasive bladder cancer outcomes. Clin Epigenetics. 14:142022. View Article : Google Scholar : PubMed/NCBI

Unnikrishnan A, Freeman WM, Jackson J, Wren JD, Porter H and Richardson A: The role of DNA methylation in epigenetics of aging. Pharmacol Ther. 195:172–185. 2019. View Article : Google Scholar :

Singh NP and Vinod PK: Integrative analysis of DNA methylation and gene expression in papillary renal cell carcinoma. Mol Genet Genomics. 295:807–824. 2020. View Article : Google Scholar : PubMed/NCBI

Deng Q, Du Y, Wang Z, Chen Y, Wang J, Liang H and Zhang D: Identification and validation of a DNA methylation-driven gene-based prognostic model for clear cell renal cell carcinoma. BMC Genomics. 24:3072023. View Article : Google Scholar : PubMed/NCBI

Lyko F: The DNA methyltransferase family: A versatile toolkit for epigenetic regulation. Nat Rev Genet. 19:81–92. 2018. View Article : Google Scholar

Castillo-Aguilera O, Depreux P, Halby L, Arimondo PB and Goossens L: DNA methylation targeting: The DNMT/HMT crosstalk challenge. Biomolecules. 7:32017. View Article : Google Scholar : PubMed/NCBI

Ferreira HJ and Esteller M: CpG islands in cancer: Heads, tails, and sides. Methods Mol Biol. 1766:49–80. 2018. View Article : Google Scholar : PubMed/NCBI

Wu H, Caffo B, Jaffee HA, Irizarry RA and Feinberg AP: Redefining CpG islands using hidden Markov models. Biostatistics. 11:499–514. 2010. View Article : Google Scholar : PubMed/NCBI

Rodriguez-Paredes M and Esteller M: Cancer epigenetics reaches mainstream oncology. Nat Med. 17:330–339. 2011. View Article : Google Scholar : PubMed/NCBI

Li J, Liang Y, Fan J, Xu C, Guan B, Zhang J, Guo B, Shi Y, Wang P, Tan Y, et al: DNA methylation subtypes guiding prognostic assessment and linking to responses the DNA methyltransferase inhibitor SGI-110 in urothelial carcinoma. BMC Med. 20:2222022. View Article : Google Scholar : PubMed/NCBI

Yu JT, Hu XW, Chen HY, Yang Q, Li HD, Dong YH, Zhang Y, Wang JN, Jin J, Wu YG, et al: DNA methylation of FTO promotes renal inflammation by enhancing m⁶A of PPAR-α in alcohol-induced kidney injury. Pharmacol Res. 163:1052862021. View Article : Google Scholar

Gu Y, Niu S, Wang Y, Duan L, Pan Y, Tong Z, Zhang X, Yang Z, Peng B, Wang X, et al: DMDRMR-mediated regulation of m⁶A-Modified CDK4 by m⁶A reader IGF2BP3 drives ccRCC progression. Cancer Res. 81:923–934. 2021. View Article : Google Scholar

Sandholm N, Cole JB, Nair V, Sheng X, Liu H, Ahlqvist E, van Zuydam N, Dahlström EH, Fermin D, Smyth LJ, et al: Genome-wide meta-analysis and omics integration identifies novel genes associated with diabetic kidney disease. Diabetologia. 65:1495–1509. 2022. View Article : Google Scholar : PubMed/NCBI

Johnston WWS: Diseases of the kidneys and urinary system. Med J Aust. 2:57–59. 1947.PubMed/NCBI

Correa-Forero V, Pinilla-Monsalve GD, Valderrama-Chaparro JA and Amaya-Gonzalez P: Cryptococcal meningitis presenting as acute flaccid paralysis: A case report. J Infect Public Health. 13:143–148. 2020. View Article : Google Scholar

Sampaolo S, Esposito T, Gianfrancesco F, Napolitano F, Lombardi L, Lucà R, Roperto F and Di Iorio G: A novel GBE1 mutation and features of polyglucosan bodies autophagy in adult polyglucosan body disease. Neuromuscul Disord. 25:247–252. 2015. View Article : Google Scholar

Roberts NA, Hilton EN, Lopes FM, Singh S, Randles MJ, Gardiner NJ, Chopra K, Coletta R, Bajwa Z, Hall RJ, et al: Lrig2 and Hpse2, mutated in urofacial syndrome, pattern nerves in the urinary bladder. Kidney Int. 95:1138–1152. 2019. View Article : Google Scholar : PubMed/NCBI

Liao L: Evaluation and management of neurogenic bladder: What is new in China? Int J Mol Sci. 16:18580–18600. 2015. View Article : Google Scholar : PubMed/NCBI

Yoshimura N, Ogawa T, Miyazato M, Kitta T, Furuta A, Chancellor MB and Tyagi P: Neural mechanisms underlying lower urinary tract dysfunction. Korean J Urol. 55:81–90. 2014. View Article : Google Scholar : PubMed/NCBI

Archer M, Dogra N, Dovey Z, Ganta T, Jang HS, Khusid JA, Lantz A, Mihalopoulos M, Stockert JA, Zahalka A, et al: Role of α- and β-adrenergic signaling in phenotypic targeting: Significance in benign and malignant urologic disease. Cell Commun Signal. 19:782021. View Article : Google Scholar

Chen N, Li G, Si Y, Ye Y, Zhang T, Chi D, Zhang W, Pan L, Qu G, Lu Y, et al: Development and evaluation of a centrifugal disk system for the rapid detection of multiple pathogens and their antibiotic resistance genes in urinary tract infection. Front Microbiol. 14:11574032023. View Article : Google Scholar : PubMed/NCBI

Simões E Silva AC, Oliveira EA and Mak RH: Urinary tract infection in pediatrics: An overview. J Pediatr (Rio J). 96(Suppl 1): S65–S79. 2020. View Article : Google Scholar

Zulfiqar M, Ubilla CV, Nicola R and Menias CO: Imaging of renal infections and inflammatory disease. Radiol Clin North Am. 58:909–923. 2020. View Article : Google Scholar : PubMed/NCBI

Bachar A, Itzhaki E, Gleizer S, Shamshoom M, Milo R and Antonovsky N: Point mutations in topoisomerase I alter the mutation spectrum in E. coli and impact the emergence of drug resistance genotypes. Nucleic Acids Res. 48:761–769. 2020. View Article : Google Scholar :

Price LB, Johnson JR, Aziz M, Clabots C, Johnston B, Tchesnokova V, Nordstrom L, Billig M, Chattopadhyay S, Stegger M, et al: The epidemic of extended-spectrum-β-lactama se-producing Escherichia coli ST131 is driven by a single highly pathogenic subclone, H30-Rx. mBio. 4:e00377–13. 2013. View Article : Google Scholar : PubMed/NCBI

Beebout CJ, Robertson GL, Reinfeld BI, Blee AM, Morales GH, Brannon JR, Chazin WJ, Rathmell WK, Rathmell JC, Gama V and Hadjifrangiskou M: Uropathogenic Escherichia coli subverts mitochondrial metabolism to enable intracellular bacterial pathogenesis in urinary tract infection. Nat Microbiol. 7:1348–1360. 2022. View Article : Google Scholar : PubMed/NCBI

Spradling K, Ganesan C and Conti S: Medical treatment and prevention of urinary stone disease. Urol Clin North Am. 49:335–344. 2022. View Article : Google Scholar : PubMed/NCBI

Hong SY, Xia QD, Yang YY, Li C, Zhang JQ, Xu JZ, Qin BL, Xun Y and Wang SG: The role of microbiome: A novel insight into urolithiasis. Crit Rev Microbiol. 49:177–196. 2023. View Article : Google Scholar

Hobbs T, Schultz LN, Lauchnor EG, Gerlach R and Lange D: Evaluation of biofilm induced urinary infection stone formation in a novel laboratory model system. J Urol. 199:178–185. 2018. View Article : Google Scholar

Sen H, Seckiner I, Bayrak O, Erturhan S and Demirbağ A: Treatment alternatives for urinary system stone disease in preschool aged children: Results of 616 cases. J Pediatr Urol. 11:34.e1–e5. 2015. View Article : Google Scholar : PubMed/NCBI

Chen F, Zhang Y, Bossé D, Lalani AA, Hakimi AA, Hsieh JJ, Choueiri TK, Gibbons DL, Ittmann M and Creighton CJ: Pan-urologic cancer genomic subtypes that transcend tissue of origin. Nat Commun. 8:1992017. View Article : Google Scholar : PubMed/NCBI

Markowski MC, Boorjian SA, Burton JP, Hahn NM, Ingersoll MA, Maleki Vareki S, Pal SK and Sfanos KS: The microbiome and genitourinary cancer: A collaborative review. Eur Urol. 75:637–646. 2019. View Article : Google Scholar : PubMed/NCBI

Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A and Bray F: Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 71:209–249. 2021. View Article : Google Scholar : PubMed/NCBI

Rouprêt M, Babjuk M, Compérat E, Zigeuner R, Sylvester RJ, Burger M, Cowan NC, Gontero P, Van Rhijn BWG, Mostafid AH, et al: European association of urology guidelines on upper urinary tract urothelial carcinoma: 2017 Update. Eur Urol. 73:111–122. 2018. View Article : Google Scholar

Li Z, Xu H, Gong Y, Chen W, Zhan Y, Yu L, Sun Y, Li A, He S, Guan B, et al: Patient-derived upper tract urothelial carcinoma organoids as a platform for drug screening. Adv Sci (Weinh). 9:e21039992022. View Article : Google Scholar

Zhang ML, Miki Y, Hang JF, Vohra M, Peyton S, McIntire PJ, VandenBussche CJ and Vohra P: A review of upper urinary tract cytology performance before and after the implementation of The Paris system. Cancer Cytopathol. 129:264–274. 2021. View Article : Google Scholar

Bus MTJ, de Bruin DM, Faber DJ, Kamphuis GM, Zondervan PJ, Laguna Pes MP, de Reijke TM, Traxer O, van Leeuwen TG and de la Rosette JJ: Optical diagnostics for upper urinary tract urothelial cancer: Technology, thresholds, and clinical applications. J Endourol. 29:113–123. 2015. View Article : Google Scholar

He Y, Xu W, Xiao YT, Huang H, Gu D and Ren S: Targeting signaling pathways in prostate cancer: Mechanisms and clinical trials. Signal Transduct Target Ther. 7:1982022. View Article : Google Scholar : PubMed/NCBI

Kausar S, Abbas MN and Cui H: A review on the DNA methyltransferase family of insects: Aspect and prospects. Int J Biol Macromol. 186:289–302. 2021. View Article : Google Scholar : PubMed/NCBI

Uysal F and Ozturk S: DNA methyltransferases in mammalian oocytes. Results Probl Cell Differ. 63:211–222. 2017. View Article : Google Scholar : PubMed/NCBI

Okano M, Bell DW, Haber DA and Li E: DNA methyltransferases Dnmt3a and Dnmt3b are essential for de novo methylation and mammalian development. Cell. 99:247–257. 1999. View Article : Google Scholar : PubMed/NCBI

Ren W, Gao L and Song J: Structural basis of DNMT1 and DNMT3A-mediated DNA methylation. Genes (Basel). 9:6202018. View Article : Google Scholar : PubMed/NCBI

Chen Z and Zhang Y: Role of mammalian DNA methyltransferases in development. Annu Rev Biochem. 89:135–158. 2020. View Article : Google Scholar

Poh WJ, Wee CP and Gao Z: DNA methyltransferase activity assays: Advances and challenges. Theranostics. 6:369–391. 2016. View Article : Google Scholar : PubMed/NCBI

Takeshima H, Niwa T, Yamashita S, Takamura-Enya T, Iida N, Wakabayashi M, Nanjo S, Abe M, Sugiyama T, Kim YJ and Ushijima T: TET repression and increased DNMT activity synergistically induce aberrant DNA methylation. J Clin Invest. 130:5370–5379. 2020. View Article : Google Scholar : PubMed/NCBI

Huang J, Fan T, Yan Q, Zhu H, Fox S, Issaq HJ, Best L, Gangi L, Munroe D and Muegge K: Lsh, an epigenetic guardian of repetitive elements. Nucleic Acids Res. 32:5019–5028. 2004. View Article : Google Scholar : PubMed/NCBI

Tao Y, Xi S, Shan J, Maunakea A, Che A, Briones V, Lee EY, Geiman T, Huang J, Stephens R, et al: Lsh, chromatin remodeling family member, modulates genome-wide cytosine methylation patterns at nonrepeat sequences. Proc Natl Acad Sci USA. 108:5626–5631. 2011. View Article : Google Scholar : PubMed/NCBI

Han M, Li J, Cao Y, Huang Y, Li W, Zhu H, Zhao Q, Han JJ, Wu Q, Li J, et al: A role for LSH in facilitating DNA methylation by DNMT1 through enhancing UHRF1 chromatin association. Nucleic Acids Res. 48:12116–12134. 2020. View Article : Google Scholar : PubMed/NCBI

Xing H, Wang C, Wu H, Chen D, Li S and Xu S: Effects of atrazine and chlorpyrifos on DNA methylation in the brain and gonad of the common carp. Comp Biochem Physiol C Toxicol Pharmacol. 168:11–19. 2015. View Article : Google Scholar

Wang C, Zhang Z, Yao H, Zhao F, Wang L, Wang X, Xing H and Xu S: Effects of atrazine and chlorpyrifos on DNA methylation in the liver, kidney and gill of the common carp (Cyprinus carpio L.). Ecotoxicol Environ Saf. 108:142–151. 2014. View Article : Google Scholar : PubMed/NCBI

Wirbisky-Hershberger SE, Sanchez OF, Horzmann KA, Thanki D, Yuan C and Freeman JL: Atrazine exposure decreases the activity of DNMTs, global DNA methylation levels, and dnmt expression. Food Chem Toxicol. 109:727–734. 2017. View Article : Google Scholar : PubMed/NCBI

Svedružić ŽM: Dnmt1 structure and function. Prog Mol Biol Transl Sci. 101:221–254. 2011. View Article : Google Scholar

Duraisamy AJ, Mishra M, Kowluru A and Kowluru RA: Epigenetics and Regulation of oxidative stress in diabetic retinopathy. Invest Ophthalmol Vis Sci. 59:4831–4840. 2018. View Article : Google Scholar : PubMed/NCBI

Zhao L, Sun MA, Li Z, Bai X, Yu M, Wang M, Liang L, Shao X, Arnovitz S, Wang Q, et al: The dynamics of DNA methylation fidelity during mouse embryonic stem cell self-renewal and differentiation. Genome Res. 24:1296–1307. 2014. View Article : Google Scholar : PubMed/NCBI

Mohan KN: DNMT1: Catalytic and non-catalytic roles in different biological processes. Epigenomics. 14:629–643. 2022. View Article : Google Scholar : PubMed/NCBI

Arand J, Spieler D, Karius T, Branco MR, Meilinger D, Meissner A, Jenuwein T, Xu G, Leonhardt H, Wolf V and Walter J: In vivo control of CpG and non-CpG DNA methylation by DNA methyltransferases. PLoS Genet. 8:e10027502012. View Article : Google Scholar : PubMed/NCBI

Wang Q, Yu G, Ming X, Xia W, Xu X, Zhang Y, Zhang W, Li Y, Huang C, Xie H, et al: Imprecise DNMT1 activity coupled with neighbor-guided correction enables robust yet flexible epigenetic inheritance. Nat Genet. 52:828–839. 2020. View Article : Google Scholar : PubMed/NCBI

Echeverria F, Ortiz M, Valenzuela R and Videla LA: Long-chain polyunsaturated fatty acids regulation of PPARs, signaling: Relationship to tissue development and aging. Prostaglandins Leukot Essent Fatty Acids. 114:28–34. 2016. View Article : Google Scholar : PubMed/NCBI

Ceccarelli V, Ronchetti S, Marchetti MC, Calvitti M, Riccardi C, Grignani F and Vecchini A: Molecular mechanisms underlying eicosapentaenoic acid inhibition of HDAC1 and DNMT expression and activity in carcinoma cells. Biochim Biophys Acta Gene Regul Mech. 1863:1944812020. View Article : Google Scholar : PubMed/NCBI

Zhao D, Gao Y, Su Y, Zhou Y, Yang T, Li Y, Wang Y, Sun Y, Chen L, Zhang F, et al: Oroxylin A regulates cGAS DNA hypermethylation induced by methionine metabolism to promote HSC senescence. Pharmacol Res. 187:1065902023. View Article : Google Scholar

van der Wijst MG, Venkiteswaran M, Chen H, Xu GL, Plösch T and Rots MG: Local chromatin microenvironment determines DNMT activity: From DNA methyltransferase to DNA demethylase or DNA dehydroxymethylase. Epigenetics. 10:671–676. 2015. View Article : Google Scholar : PubMed/NCBI

Wolffgramm J, Buchmuller B, Palei S, Muñoz-López Á, Kanne J, Janning P, Schweiger MR and Summerer D: Light-activation of DNA-methyltransferases. Angew Chem Int Ed Engl. 60:13507–13512. 2021. View Article : Google Scholar : PubMed/NCBI

Correa LO, Jordan MS and Carty SA: DNA methylation in T-cell development and differentiation. Crit Rev Immunol. 40:135–156. 2020. View Article : Google Scholar : PubMed/NCBI

Lee PP, Fitzpatrick DR, Beard C, Jessup HK, Lehar S, Makar KW, Pérez-Melgosa M, Sweetser MT, Schlissel MS, Nguyen S, et al: A critical role for Dnmt1 and DNA methylation in T cell development, function, and survival. Immunity. 15:763–774. 2001. View Article : Google Scholar : PubMed/NCBI

Ktena YP, Koldobskiy MA, Barbato MI, Fu HH, Luznik L, Llosa NJ, Haile A, Klein OR, Liu C, Gamper CJ and Cooke KR: Donor T cell DNMT3a regulates alloreactivity in mouse models of hematopoietic stem cell transplantation. J Clin Invest. 132:e1580472022. View Article : Google Scholar : PubMed/NCBI

Lu CH, Wu CJ, Chan CC, Nguyen DT, Lin KR, Lin SJ, Chen LC, Yen JJ and Kuo ML: DNA methyltransferase inhibitor promotes human CD4⁺CD25^hFOXP3⁺ regulatory T lymphocyte induction under suboptimal TCR stimulation. Front Immunol. 7:4882016.

Lv Q, Shi C, Qiao S, Cao N, Guan C, Dai Y and Wei Z: Alpinetin exerts anti-colitis efficacy by activating AhR, regulating miR-302/DNMT-1/CREB signals, and therefore promoting Treg differentiation. Cell Death Dis. 9:8902018. View Article : Google Scholar : PubMed/NCBI

Ehrlich M: DNA hypermethylation in disease: Mechanisms and clinical relevance. Epigenetics. 14:1141–1163. 2019. View Article : Google Scholar : PubMed/NCBI

Ellinger J, El Kassem N, Heukamp LC, Matthews S, Cubukluoz F, Kahl P, Perabo FG, Müller SC, von Ruecker A and Bastian PJ: Hypermethylation of cell-free serum DNA indicates worse outcome in patients with bladder cancer. J Urol. 179:346–352. 2008. View Article : Google Scholar

Marsit CJ, Karagas MR, Danaee H, Liu M, Andrew A, Schned A, Nelson HH and Kelsey KT: Carcinogen exposure and gene promoter hypermethylation in bladder cancer. Carcinogenesis. 27:112–116. 2006. View Article : Google Scholar

Yates DR, Rehman I, Abbod MF, Meuth M, Cross SS, Linkens DA, Hamdy FC and Catto JW: Promoter hypermethylation identifies progression risk in bladder cancer. Clin Cancer Res. 13:2046–2053. 2007. View Article : Google Scholar : PubMed/NCBI

Thompson D, Lawrentschuk N and Bolton D: New approaches to targeting epigenetic regulation in bladder cancer. Cancers (Basel). 15:18562023. View Article : Google Scholar : PubMed/NCBI

Nunes SP, Henrique R, Jerónimo C and Paramio JM: DNA methylation as a therapeutic target for bladder cancer. Cells. 9:18502020. View Article : Google Scholar : PubMed/NCBI

Wang R and Liu X: Epigenetic regulation of prostate cancer. Genes Dis. 7:606–613. 2020. View Article : Google Scholar : PubMed/NCBI

Yang Z, Chu B, Tu Y, Li L, Chen D, Huang S, Huang W, Fan W, Li Q, Zhang C, et al: Dual inhibitors of DNMT and HDAC remodels the immune microenvironment of colorectal cancer and enhances the efficacy of anti-PD-L1 therapy. Pharmacol Res. 206:1072712024. View Article : Google Scholar : PubMed/NCBI

Wang JH, Zeng Z, Sun J, Chen Y and Gao X: A novel small-molecule antagonist enhances the sensitivity of osteosarcoma to cabozantinib in vitro and in vivo by targeting DNMT-1 correlated with disease severity in human patients. Pharmacol Res. 173:1058692021. View Article : Google Scholar : PubMed/NCBI

Li KK, Li F, Li QS, Yang K and Jin B: DNA methylation as a target of epigenetic therapeutics in cancer. Anticancer Agents Med Chem. 13:242–247. 2013. View Article : Google Scholar

Nagaraju GP, Wu C, Merchant N, Chen Z, Lesinski GB and El-Rayes BF: Epigenetic effects of inhibition of heat shock protein 90 (HSP90) in human pancreatic and colon cancer. Cancer Lett. 402:110–116. 2017. View Article : Google Scholar : PubMed/NCBI

Manara MC, Valente S, Cristalli C, Nicoletti G, Landuzzi L, Zwergel C, Mazzone R, Stazi G, Arimondo PB, Pasello M, et al: A quinoline-based DNA methyltransferase inhibitor as a possible adjuvant in osteosarcoma therapy. Mol Cancer Ther. 17:1881–1892. 2018. View Article : Google Scholar : PubMed/NCBI

Jin T, Hao J and Fan D: Nicotine induces aberrant hypermethylation of tumor suppressor genes in pancreatic epithelial ductal cells. Biochem Biophys Res Commun. 499:934–940. 2018. View Article : Google Scholar : PubMed/NCBI

Bazzichetto C, Conciatori F, Pallocca M, Falcone I, Fanciulli M, Cognetti F, Milella M and Ciuffreda L: PTEN as a prognostic/predictive biomarker in cancer: An unfulfilled promise? Cancers (Basel). 11:4352019. View Article : Google Scholar : PubMed/NCBI

Carbajo-Garcia MC, Corachán A, Segura-Benitez M, Monleón J, Escrig J, Faus A, Pellicer A, Cervelló I and Ferrero H: 5-aza-2′-deoxycitidine inhibits cell proliferation, extracellular matrix formation and Wnt/β-catenin pathway in human uterine leiomyomas. Reprod Biol Endocrinol. 19:1062021. View Article : Google Scholar

Bechtel W, McGoohan S, Zeisberg EM, Müller GA, Kalbacher H, Salant DJ, Müller CA, Kalluri R and Zeisberg M: Methylation determines fibroblast activation and fibrogenesis in the kidney. Nat Med. 16:544–550. 2010. View Article : Google Scholar : PubMed/NCBI

Kato M and Natarajan R: Epigenetics and epigenomics in diabetic kidney disease and metabolic memory. Nat Rev Nephrol. 15:327–345. 2019. View Article : Google Scholar : PubMed/NCBI

Bowden SA, Rodger EJ, Chatterjee A, Eccles MR and Stayner C: Recent discoveries in epigenetic modifications of polycystic kidney disease. Int J Mol Sci. 22:133272021. View Article : Google Scholar : PubMed/NCBI

Marumo T, Yagi S, Kawarazaki W, Nishimoto M, Ayuzawa N, Watanabe A, Ueda K, Hirahashi J, Hishikawa K, Sakurai H, et al: Diabetes induces aberrant DNA methylation in the proximal tubules of the kidney. J Am Soc Nephrol. 26:2388–2397. 2015. View Article : Google Scholar : PubMed/NCBI

Sidler M, Aitken KJ, Jiang JX, Yadav P, Lloyd E, Ibrahim M, Choufani S, Weksberg R and Bägli D: Inhibition of DNA methylation during chronic obstructive bladder disease (COBD) improves function, pathology and expression. Sci Rep. 11:173072021. View Article : Google Scholar : PubMed/NCBI

Li Y, Luo Q, Li Z, Wang Y, Zhu C, Li T and Li X: Long non-coding RNA IRAIN inhibits VEGFA expression via enhancing its DNA methylation leading to tumor suppression in renal carcinoma. Front Oncol. 10:10822020. View Article : Google Scholar : PubMed/NCBI

Huang YQ, Guan H, Liu CH, Liu DC, Xu B, Jiang L, Lin ZX and Chen M: Association between RASSF1A promoter methylation and renal cell cancer susceptibility: A meta-analysis. Genet Mol Res. 15:gmr.150269942016.

Bayarsaihan D: Epigenetic mechanisms in inflammation. J Dent Res. 90:9–17. 2011. View Article : Google Scholar :

Bradley MS, Burke EE, Grenier C, Amundsen CL, Murphy SK and Siddiqui NY: A genome-scale DNA methylation study in women with interstitial cystitis/bladder pain syndrome. Neurourol Urodyn. 37:1485–1493. 2018. View Article : Google Scholar : PubMed/NCBI

Tolg C and Bägli DJ: Uropathogenic Escherichia coli infection: Potential importance of epigenetics. Epigenomics. 4:229–235. 2012. View Article : Google Scholar : PubMed/NCBI

Emam M, Cánovas A, Islas-Trejo AD, Fonseca PAS, Medrano JF and Mallard B: Transcriptomic profiles of monocyte-derived macrophages in response to Escherichia coli is associated with the host genetics. Sci Rep. 10:2712020. View Article : Google Scholar : PubMed/NCBI

Tolg C, Sabha N, Cortese R, Panchal T, Ahsan A, Soliman A, Aitken KJ, Petronis A and Bägli DJ: Uropathogenic E. coli infection provokes epigenetic downregulation of CDKN2A (p16INK4A) in uroepithelial cells. Lab Invest. 91:825–836. 2011. View Article : Google Scholar : PubMed/NCBI

Tatemichi M, Hata H, Tazawa H and Nakadate T: Lipopolysaccharide induces aberrant hypermethylation of Hic-1 in mouse embryonic fibroblasts lacking p53 gene. Anticancer Res. 28:2101–2108. 2008.PubMed/NCBI

Yang RB, Mark MR, Gray A, Huang A, Xie MH, Zhang M, Goddard A, Wood WI, Gurney AL and Godowski PJ: Toll-like receptor-2 mediates lipopolysaccharide-induced cellular signalling. Nature. 395:284–288. 1998. View Article : Google Scholar : PubMed/NCBI

Valinluck V and Sowers LC: Inflammation-mediated cytosine damage: A mechanistic link between inflammation and the epigenetic alterations in human cancers. Cancer Res. 67:5583–5586. 2007. View Article : Google Scholar : PubMed/NCBI

Ding H, Chen J, Su M, Lin Z, Zhan H, Yang F, Li W, Xie J, Huang Y, Liu X, et al: BDNF promotes activation of astrocytes and microglia contributing to neuroinflammation and mechanical allodynia in cyclophosphamide-induced cystitis. J Neuroinflammation. 17:192020. View Article : Google Scholar : PubMed/NCBI

Haldar S, Dru C, Mishra R, Tripathi M, Duong F, Angara B, Fernandez A, Arditi M and Bhowmick NA: Histone deacetylase inhibitors mediate DNA damage repair in ameliorating hemorrhagic cystitis. Sci Rep. 6:392572016. View Article : Google Scholar : PubMed/NCBI

Choi IS, Yu K, Kim J, De Guzman E, Weisenberger DJ, Oghamian S, Kim HJ, Lee KH, Carroll C, Trinh BN, et al: Alterations in deoxyribonucleic acid (DNA) methylation patterns of Calca, Timp3, Mmp2, and Igf2r are associated with chronic cystitis in a cyclophosphamide-induced mouse model. Urology. 82:253.e9–e15. 2013. View Article : Google Scholar : PubMed/NCBI

Mennuni S, Rubattu S, Pierelli G, Tocci G, Fofi C and Volpe M: Hypertension and kidneys: Unraveling complex molecular mechanisms underlying hypertensive renal damage. J Hum Hypertens. 28:74–79. 2014. View Article : Google Scholar

Tomaszewski M and Itoh H: ISH2022KYOTO hypertension zero declaration. Cardiovasc Res. 119:e1362023. View Article : Google Scholar

NCD Risk Factor Collaboration (NCD-RisC): Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019: A pooled analysis of 1201 population-representative studies with 104 million participants. Lancet. 398:957–980. 2021. View Article : Google Scholar : PubMed/NCBI

Pinheiro LC and Oliveira-Paula GH: Sources and effects of oxidative stress in hypertension. Curr Hypertens Rev. 16:166–180. 2020. View Article : Google Scholar

Rodriguez-Iturbe B, Sepassi L, Quiroz Y, Ni Z, Wallace DC and Vaziri ND: Association of mitochondrial SOD deficiency with salt-sensitive hypertension and accelerated renal senescence. J Appl Physiol (1985). 102:255–260. 2007. View Article : Google Scholar

Godin N, Liu F, Lau GJ, Brezniceanu ML, Chénier I, Filep JG, Ingelfinger JR, Zhang SL and Chan JS: Catalase overexpression prevents hypertension and tubular apoptosis in angiotensinogen transgenic mice. Kidney Int. 77:1086–1097. 2010. View Article : Google Scholar : PubMed/NCBI

Chen Y, Li X, Wang S, Miao R and Zhong J: Targeting iron metabolism and ferroptosis as novel therapeutic approaches in cardiovascular diseases. Nutrients. 15:5912023. View Article : Google Scholar : PubMed/NCBI

Vaziri ND, Lin CY, Farmand F and Sindhu RK: Superoxide dismutase, catalase, glutathione peroxidase and NADPH oxidase in lead-induced hypertension. Kidney Int. 63:186–194. 2003. View Article : Google Scholar

Pushpakumar S, Ren L, Juin SK, Majumder S, Kulkarni R and Sen U: Methylation-dependent antioxidant-redox imbalance regulates hypertensive kidney injury in aging. Redox Biol. 37:1017542020. View Article : Google Scholar : PubMed/NCBI

Cencioni C, Spallotta F, Martelli F, Valente S, Mai A, Zeiher AM and Gaetano C: Oxidative stress and epigenetic regulation in ageing and age-related diseases. Int J Mol Sci. 14:17643–17663. 2013. View Article : Google Scholar : PubMed/NCBI

Miyoshi M, Sato M, Saito K, Otani L, Shirahige K, Miura F, Ito T, Jia H and Kato H: Maternal protein restriction alters the renal ptger1 DNA methylation state in SHRSP offspring. Nutrients. 10:14362018. View Article : Google Scholar : PubMed/NCBI

Jia H, Miyoshi M, Li X, Furukawa K, Otani L, Shirahige K, Miura F, Ito T and Kato H: The epigenetic legacy of maternal protein restriction: Renal ptger1 DNA methylation changes in hypertensive rat offspring. Nutrients. 15:39572023. View Article : Google Scholar : PubMed/NCBI

Saeedi P, Petersohn I, Salpea P, Malanda B, Karuranga S, Unwin N, Colagiuri S, Guariguata L, Motala AA, Ogurtsova K, et al: Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: Results from the International diabetes federation diabetes atlas, 9th edition. Diabetes Res Clin Pract. 157:1078432019. View Article : Google Scholar

Lin E and Erickson KF: Payer mix among patients receiving dialysis. JAMA. 324:900–901. 2020. View Article : Google Scholar : PubMed/NCBI

Thomas MC, Brownlee M, Susztak K, Sharma K, Jandeleit-Dahm KA, Zoungas S, Rossing P, Groop PH and Cooper ME: Diabetic kidney disease. Nat Rev Dis Primers. 1:150182015. View Article : Google Scholar : PubMed/NCBI

Sun G, Reddy MA, Yuan H, Lanting L, Kato M and Natarajan R: Epigenetic histone methylation modulates fibrotic gene expression. J Am Soc Nephrol. 21:2069–2080. 2010. View Article : Google Scholar : PubMed/NCBI

Schlosser P, Tin A, Matias-Garcia PR, Thio CHL, Joehanes R, Liu H, Weihs A, Yu Z, Hoppmann A, Grundner-Culemann F, et al: Meta-analyses identify DNA methylation associated with kidney function and damage. Nat Commun. 12:71742021. View Article : Google Scholar : PubMed/NCBI

Smyth LJ, Dahlström EH, Syreeni A, Kerr K, Kilner J, Doyle R, Brennan E, Nair V, Fermin D, Nelson RG, et al: Epigenome-wide meta-analysis identifies DNA methylation biomarkers associated with diabetic kidney disease. Nat Commun. 13:78912022. View Article : Google Scholar : PubMed/NCBI

He C, Wang D, Wang R, Huang Y, Huang X, Shen S, Lv J and Wu M: Epigallocatechin gallate induces the demethylation of actinin alpha 4 to inhibit diabetic nephropathy renal fibrosis via the NF-KB signaling pathway in vitro. Dose Response. 20:155932582211057042022. View Article : Google Scholar : PubMed/NCBI

Zhang L, Zhang Q, Liu S, Chen Y, Li R, Lin T, Yu C, Zhang H, Huang Z, Zhao X, et al: DNA methyltransferase 1 may be a therapy target for attenuating diabetic nephropathy and podocyte injury. Kidney Int. 92:140–153. 2017. View Article : Google Scholar : PubMed/NCBI

Peng R, Liu H, Peng H, Zhou J, Zha H, Chen X, Zhang L, Sun Y, Yin P, Wen L, et al: Promoter hypermethylation of let-7a-3 is relevant to its down-expression in diabetic nephropathy by targeting UHRF1. Gene. 570:57–63. 2015. View Article : Google Scholar : PubMed/NCBI

Zhou J, Peng R, Li T, Luo X, Peng H, Zha H, Yin P, Wen L and Zhang Z: A potentially functional polymorphism in the regulatory region of let-7a-2 is associated with an increased risk for diabetic nephropathy. Gene. 527:456–461. 2013. View Article : Google Scholar : PubMed/NCBI

Lane BM, Murray S, Benson K, Bierzynska A, Chryst-Stangl M, Wang L, Wu G, Cavalleri G, Doyle B, Fennelly N, et al: A rare autosomal dominant variant in regulator of calcineurin type 1 (RCAN1) gene confers enhanced calcineurin activity and may cause FSGS. J Am Soc Nephrol. 32:1682–1695. 2021. View Article : Google Scholar : PubMed/NCBI

Li H, Zhang W, Zhong F, Das GC, Xie Y, Li Z, Cai W, Jiang G, Choi J, Sidani M, et al: Epigenetic regulation of RCAN1 expression in kidney disease and its role in podocyte injury. Kidney Int. 94:1160–1176. 2018. View Article : Google Scholar : PubMed/NCBI

Hasan NS, Gamal El Dine H, Kamel SA, Hamed M, Youssef RN, Mahmoud Hassan E, Abdelrahman AH, Musa NI, Ali A and Awadallah E: Association of genetic and epigenetic changes of insulin like growth factor binding protein-1 in Egyptian patients with type 2 diabetes mellitus. Diabetes Res Clin Pract. 200:1106772023. View Article : Google Scholar : PubMed/NCBI

Yang XH, Cao RF, Yu Y, Sui M, Zhang T, Xu JY and Wang XM: A study on the correlation between MTHFR promoter methylation and diabetic nephropathy. Am J Transl Res. 8:4960–4967. 2016.PubMed/NCBI

Yang XH, Zhang BL, Zhang XM, Tong JD, Gu YH, Guo LL and Jin HM: EGCG attenuates renal damage via reversing Klotho hypermethylation in diabetic db/db mice and HK-2 cells. Oxid Med Cell Longev. 2020:60927152020. View Article : Google Scholar : PubMed/NCBI

Tomson CRV, Cheung AK, Mann JFE, Chang TI, Cushman WC, Furth SL, Hou FF, Knoll GA, Muntner P, Pecoits-Filho R, et al: Management of blood pressure in patients with chronic kidney disease not receiving dialysis: Synopsis of the 2021 KDIGO clinical practice guideline. Ann Intern Med. 174:1270–1281. 2021. View Article : Google Scholar : PubMed/NCBI

Ying M, Shao X, Qin H, Yin P, Lin Y, Wu J, Ren J and Zheng Y: Disease burden and epidemiological trends of chronic kidney disease at the global, regional, national levels from 1990 to 2019. Nephron. 148:113–123. 2024. View Article : Google Scholar

Ko YA, Mohtat D, Suzuki M, Park AS, Izquierdo MC, Han SY, Kang HM, Si H, Hostetter T, Pullman JM, et al: Cytosine methylation changes in enhancer regions of core pro-fibrotic genes characterize kidney fibrosis development. Genome Biol. 14:R1082013. View Article : Google Scholar : PubMed/NCBI

Morgado-Pascual JL, Marchant V, Rodrigues-Diez R, Dolade N, Suarez-Alvarez B, Kerr B, Valdivielso JM, Ruiz-Ortega M and Rayego-Mateos S: Epigenetic modification mechanisms involved in inflammation and fibrosis in renal pathology. Mediators Inflamm. 2018:29310492018. View Article : Google Scholar

Panizo S, Martinez-Arias L, Alonso-Montes C, Cannata P, Martín-Carro B, Fernández-Martín JL, Naves-Díaz M, Carrillo-López N and Cannata-Andía JB: Fibrosis in chronic kidney disease: Pathogenesis and consequences. Int J Mol Sci. 22:4082021. View Article : Google Scholar : PubMed/NCBI

Yin S, Zhang Q, Yang J, Lin W, Li Y, Chen F and Cao W: TGFβ-incurred epigenetic aberrations of miRNA and DNA methyltransferase suppress Klotho and potentiate renal fibrosis. Biochim Biophys Acta Mol Cell Res. 1864:1207–1216. 2017. View Article : Google Scholar : PubMed/NCBI

Xiao X, Wang W, Guo C, Wu J, Zhang S, Shi H, Kwon S, Chen J and Dong Z: Hypermethylation leads to the loss of HOXA5, resulting in JAG1 expression and NOTCH signaling contributing to kidney fibrosis. Kidney Int. 106:98–114. 2024. View Article : Google Scholar : PubMed/NCBI

Li Y, Chen F, Wei A, Bi F, Zhu X, Yin S, Lin W and Cao W: Klotho recovery by genistein via promoter histone acetylation and DNA demethylation mitigates renal fibrosis in mice. J Mol Med (Berl). 97:541–552. 2019. View Article : Google Scholar : PubMed/NCBI

Takiguchi M, Achanzar WE, Qu W, Li G and Waalkes MP: Effects of cadmium on DNA-(Cytosine-5) methyltransferase activity and DNA methylation status during cadmium-induced cellular transformation. Exp Cell Res. 286:355–365. 2003. View Article : Google Scholar : PubMed/NCBI

Zhang C, Liang Y, Lei L, Zhu G, Chen X, Jin T and Wu Q: Hypermethylations of RASAL1 and KLOTHO is associated with renal dysfunction in a Chinese population environmentally exposed to cadmium. Toxicol Appl Pharmacol. 271:78–85. 2013. View Article : Google Scholar : PubMed/NCBI

Azuma M, Koyama D, Kikuchi J, Yoshizawa H, Thasinas D, Shiizaki K, Kuro-o M, Furukawa Y and Kusano E: Promoter methylation confers kidney-specific expression of the Klotho gene. FASEB J. 26:4264–4274. 2012. View Article : Google Scholar : PubMed/NCBI

Chen Z, Li G and Liu J: Autonomic dysfunction in Parkinson's disease: Implications for pathophysiology, diagnosis, and treatment. Neurobiol Dis. 134:1047002020. View Article : Google Scholar

Wang W, Zhao X, Shao Y, Duan X, Wang Y, Li J, Li J, Li D, Li X and Wong J: Mutation-induced DNMT1 cleavage drives neurodegenerative disease. Sci Adv. 7:eabe85112021. View Article : Google Scholar : PubMed/NCBI

Ye S, Zhong J, Huang J, Chen L, Yi L, Li X, Lv J, Miao J, Li H, Chen D and Li C: Protective effect of plastrum testudinis extract on dopaminergic neurons in a Parkinson's disease model through DNMT1 nuclear translocation and SNCA's methylation. Biomed Pharmacother. 141:1118322021. View Article : Google Scholar : PubMed/NCBI

Patel HD, Gupta M, Joice GA, Srivastava A, Alam R, Allaf ME and Pierorazio PM: Clinical stage migration and survival for renal cell carcinoma in the United States. Eur Urol Oncol. 2:343–348. 2019. View Article : Google Scholar : PubMed/NCBI

Turajlic S, Swanton C and Boshoff C: Kidney cancer: The next decade. J Exp Med. 215:2477–2479. 2018. View Article : Google Scholar : PubMed/NCBI

Lin RK and Wang YC: Dysregulated transcriptional and post-translational control of DNA methyltransferases in cancer. Cell Biosci. 4:462014. View Article : Google Scholar : PubMed/NCBI

Arai E and Kanai Y: Genetic and epigenetic alterations during renal carcinogenesis. Int J Clin Exp Pathol. 4:58–73. 2010.

Bahadoram S, Davoodi M, Hassanzadeh S, Bahadoram M, Barahman M and Mafakher L: Renal cell carcinoma: An overview of the epidemiology, diagnosis, and treatment. G Ital Nefrol. 39:2022–vol3. 2022.PubMed/NCBI

Christoph F, Kempkensteffen C, Weikert S, Köllermann J, Krause H, Miller K, Schostak M and Schrader M: Methylation of tumour suppressor genes APAF-1 and DAPK-1 and in vitro effects of demethylating agents in bladder and kidney cancer. Br J Cancer. 95:1701–1707. 2006. View Article : Google Scholar : PubMed/NCBI

Christoph F, Weikert S, Kempkensteffen C, Krause H, Schostak M, Köllermann J, Miller K and Schrader M: Promoter hypermethylation profile of kidney cancer with new proapoptotic p53 target genes and clinical implications. Clin Cancer Res. 12:5040–5046. 2006. View Article : Google Scholar : PubMed/NCBI

Liu Q, Jin J, Ying J, Cui Y, Sun M, Zhang L, Fan Y, Xu B and Zhang Q: Epigenetic inactivation of the candidate tumor suppressor gene ASC/TMS1 in human renal cell carcinoma and its role as a potential therapeutic target. Oncotarget. 6:22706–22723. 2015. View Article : Google Scholar : PubMed/NCBI

Joosten SC, Deckers IA, Aarts MJ, Hoeben A, van Roermund JG, Smits KM, Melotte V, van Engeland M and Tjan-Heijnen VC: Prognostic DNA methylation markers for renal cell carcinoma: A systematic review. Epigenomics. 9:1243–1257. 2017. View Article : Google Scholar : PubMed/NCBI

Mo S, Su Z, Heng B, Chen W, Shi L, Du X and Lai C: SFRP1 promoter methylation and renal carcinoma risk: A systematic review and meta-analysis. J Nippon Med Sch. 85:78–86. 2018. View Article : Google Scholar : PubMed/NCBI

Morris MR, Ricketts CJ, Gentle D, McRonald F, Carli N, Khalili H, Brown M, Kishida T, Yao M, Banks RE, et al: Genome-wide methylation analysis identifies epigenetically inactivated candidate tumour suppressor genes in renal cell carcinoma. Oncogene. 30:1390–1401. 2011. View Article : Google Scholar

Peters I, Eggers H, Atschekzei F, Hennenlotter J, Waalkes S, Tränkenschuh W, Grosshennig A, Merseburger AS, Stenzl A, Kuczyk MA and Serth J: GATA5 CpG island methylation in renal cell cancer: A potential biomarker for metastasis and disease progression. BJU Int. 110:E144–E152. 2012. View Article : Google Scholar : PubMed/NCBI

Peters I, Gebauer K, Dubrowinskaja N, Atschekzei F, Kramer MW, Hennenlotter J, Tezval H, Abbas M, Scherer R, Merseburger AS, et al: GATA5 CpG island hypermethylation is an independent predictor for poor clinical outcome in renal cell carcinoma. Oncol Rep. 31:1523–1530. 2014. View Article : Google Scholar : PubMed/NCBI

Rohilla S, Singh M, Priya S, Almalki WH, Haniffa SM, Subramaniyan V, Fuloria S, Fuloria NK, Sekar M, Singh SK, et al: Exploring the mechanical perspective of a new anti-tumor agent: Melatonin. J Environ Pathol Toxicol Oncol. 42:1–16. 2023. View Article : Google Scholar : PubMed/NCBI

Majid S, Dar AA, Ahmad AE, Hirata H, Kawakami K, Shahryari V, Saini S, Tanaka Y, Dahiya AV, Khatri G and Dahiya R: BTG3 tumor suppressor gene promoter demethylation, histone modification and cell cycle arrest by genistein in renal cancer. Carcinogenesis. 30:662–670. 2009. View Article : Google Scholar : PubMed/NCBI

Wang L, Lu B, He M, Wang Y, Wang Z and Du L: Prostate cancer incidence and mortality: Global status and temporal trends in 89 countries from 2000 to 2019. Front Public Health. 10:8110442022. View Article : Google Scholar : PubMed/NCBI

Chang AJ, Autio KA, Roach M III and Scher HI: High-risk prostate cancer-classification and therapy. Nat Rev Clin Oncol. 11:308–323. 2014. View Article : Google Scholar : PubMed/NCBI

Jemal A, Culp MB, Ma J, Islami F and Fedewa SA: Prostate cancer incidence 5 years after US preventive services task force recommendations against screening. J Natl Cancer Inst. 113:64–71. 2021. View Article : Google Scholar :

Zargar H, van den Bergh R, Moon D, Lawrentschuk N, Costello A and Murphy D: The impact of the United States preventive services task force (USPTSTF) recommendations against prostate-specific antigen (PSA) testing on PSA testing in Australia. BJU Int. 119:110–115. 2017. View Article : Google Scholar

Curry SJ, Krist AH and Owens DK: Annual report to the nation on the status of cancer, part II: Recent changes in prostate cancer trends and disease characteristics. Cancer. 125:317–318. 2019. View Article : Google Scholar

Hatakeyama S, Yoneyama T, Tobisawa Y and Ohyama C: Recent progress and perspectives on prostate cancer biomarkers. Int J Clin Oncol. 22:214–221. 2017. View Article : Google Scholar :

Jerónimo C, Bastian PJ, Bjartell A, Carbone GM, Catto JW, Clark SJ, Henrique R, Nelson WG and Shariat SF: Epigenetics in prostate cancer: Biologic and clinical relevance. Eur Urol. 60:753–766. 2011. View Article : Google Scholar : PubMed/NCBI

Zhao SG, Chen WS, Li H, Foye A, Zhang M, Sjöström M, Aggarwal R, Playdle D, Liao A, Alumkal JJ, et al: The DNA methylation landscape of advanced prostate cancer. Nat Genet. 52:778–789. 2020. View Article : Google Scholar : PubMed/NCBI

Zhao Y, Hu X, Yu H, Liu X, Sun H and Shao C: Alternations of gene expression in PI3K and AR pathways and DNA methylation features contribute to metastasis of prostate cancer. Cell Mol Life Sci. 79:4362022. View Article : Google Scholar : PubMed/NCBI

Ummanni R, Jost E, Braig M, Lohmann F, Mundt F, Barett C, Schlomm T, Sauter G, Senff T, Bokemeyer C, et al: Ubiquitin carboxyl-terminal hydrolase 1 (UCHL1) is a potential tumour suppressor in prostate cancer and is frequently silenced by promoter methylation. Mol Cancer. 10:1292011. View Article : Google Scholar : PubMed/NCBI

Chen Y, Li J, Yu X, Li S, Zhang X, Mo Z and Hu Y: APC gene hypermethylation and prostate cancer: A systematic review and meta-analysis. Eur J Hum Genet. 21:929–935. 2013. View Article : Google Scholar : PubMed/NCBI

Zhang SQ, Zhang GQ and Zhang L: Correlation between methylation of the E-cadherin gene and malignancy of prostate cancer. Genet Mol Res. 15:gmr.150280462016.

Miyauchi T, Takahashi M, Mitsuzuka K, Saiki Y, Okubo T, Vertino PM, Goto A, Arai Y, Horii A and Fukushige S: Aberrant hypermethylation-mediated suppression of PYCARD is extremely frequent in prostate cancer with gleason score ≥7. Dis Markers. 2021:88589052021. View Article : Google Scholar

Singal R, Ferdinand L, Reis IM and Schlesselman JJ: Methylation of multiple genes in prostate cancer and the relationship with clinicopathological features of disease. Oncol Rep. 12:631–637. 2004.PubMed/NCBI

Zhang W, Zeng S, Gong L, Zhang D and Hu X: Gene methylation status in focus of advanced prostate cancer diagnostics and improved individual outcomes. Transl Androl Urol. 12:1813–1826. 2023. View Article : Google Scholar

van der Pol Y, Moldovan N, Ramaker J, Bootsma S, Lenos KJ, Vermeulen L, Sandhu S, Bahce I, Pegtel DM, Wong SQ, et al: The landscape of cell-free mitochondrial DNA in liquid biopsy for cancer detection. Genome Biol. 24:2292023. View Article : Google Scholar : PubMed/NCBI

Woodson K, O'Reilly KJ, Ward DE, Walter J, Hanson J, Walk EL and Tangrea JA: CD44 and PTGS2 methylation are independent prognostic markers for biochemical recurrence among prostate cancer patients with clinically localized disease. Epigenetics. 1:183–186. 2006. View Article : Google Scholar

Boiron M: Genetics and cellular cellular biology of cancer. Pathol Biol (Paris). 38:765–767. 1990.In French. PubMed/NCBI

Zorn CS, Wojno KJ, McCabe MT, Kuefer R, Gschwend JE and Day ML: 5-aza-2′-deoxycytidine delays androgen-independent disease and improves survival in the transgenic adenocarcinoma of the mouse prostate mouse model of prostate cancer. Clin Cancer Res. 13:2136–2143. 2007. View Article : Google Scholar : PubMed/NCBI

Shang D, Liu Y, Liu Q, Zhang F, Feng L, Lv W and Tian Y: Synergy of 5-aza-2′-deoxycytidine (DAC) and paclitaxel in both androgen-dependent and -independent prostate cancer cell lines. Cancer Lett. 278:82–87. 2009. View Article : Google Scholar : PubMed/NCBI

Thibault A, Figg WD, Bergan RC, Lush RM, Myers CE, Tompkins A, Reed E and Samid D: A phase II study of 5-aza-2′deoxycytidine (decitabine) in hormone independent metastatic (D2) prostate cancer. Tumori. 84:87–89. 1998. View Article : Google Scholar : PubMed/NCBI

Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 68:394–424. 2018. View Article : Google Scholar : PubMed/NCBI

Teoh JYC, Huang J, Ko WYK, Lok V, Choi P, Ng CF, Sengupta S, Mostafid H, Kamat AM, Black PC, et al: Global trends of bladder cancer incidence and mortality, and their associations with tobacco use and gross domestic product per capita. Eur Urol. 78:893–906. 2020. View Article : Google Scholar : PubMed/NCBI

Sylvester RJ, van der Meijden AP, Oosterlinck W, Witjes JA, Bouffioux C, Denis L, Newling DW and Kurth K: Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: A combined analysis of 2596 patients from seven EORTC trials. Eur Urol. 49:466–477. 2006. View Article : Google Scholar : PubMed/NCBI

Dobruch J and Oszczudlowski M: Bladder cancer: Current challenges and future directions. Medicina (Kaunas). 57:7492021. View Article : Google Scholar : PubMed/NCBI

Scher MB, Elbaum MB, Mogilevkin Y, Hilbert DW, Mydlo JH, Sidi AA, Adelson ME, Mordechai E and Trama JP: Detecting DNA methylation of the BCL2, CDKN2A and NID2 genes in urine using a nested methylation specific polymerase chain reaction assay to predict bladder cancer. J Urol. 188:2101–2107. 2012. View Article : Google Scholar : PubMed/NCBI

Bai ZJ, Liu Q, Wang XS and Liu WY: APC promoter methylation is correlated with development and progression of bladder cancer, but not linked to overall survival: A meta-analysis. Neoplasma. 66:470–480. 2019. View Article : Google Scholar : PubMed/NCBI

Kawamoto K, Enokida H, Gotanda T, Kubo H, Nishiyama K, Kawahara M and Nakagawa M: p16INK4a and p14ARF methylation as a potential biomarker for human bladder cancer. Biochem Biophys Res Commun. 339:790–796. 2006. View Article : Google Scholar

Jahed M, Ebadi N, Mivehchi M, Majidizadeh T, Shahshanipour M, Asgari M, Ghadakzadeh S and Hosseini SA: MGMT hypermethylation and BCL-2 overexpression associated with superficial bladder cancer and recurrence. Cancer Biomark. 16:627–632. 2016. View Article : Google Scholar : PubMed/NCBI

Bayramov B, Gunes S, Buyukalpelli R, Aydin O and Henkel R: Promoter methylation analysis of CDH1 and p14ARF genes in patients with urothelial bladder cancer. Onco Targets Ther. 11:4189–4196. 2018. View Article : Google Scholar : PubMed/NCBI

Chen F, Huang T, Ren Y, Wei J, Lou Z, Wang X, Fan X, Chen Y, Weng G and Yao X: Clinical significance of CDH13 promoter methylation as a biomarker for bladder cancer: A meta-analysis. BMC Urol. 16:522016. View Article : Google Scholar : PubMed/NCBI

Dai L, Ma C, Zhang Z, Zeng S, Liu A, Tang S, Ren Q, Sun Y and Xu C: DAPK promoter methylation and bladder cancer risk: A systematic review and meta-analysis. PLoS One. 11:e01672282016. View Article : Google Scholar : PubMed/NCBI

Wang D, Qiu Z and Wu C: Diagnostic value of the combination of DAPK methylation in urinary sediment and B ultrasound for recurrent urinary bladder cancer. World J Surg Oncol. 21:2672023. View Article : Google Scholar : PubMed/NCBI

Han SY, Iliopoulos D, Druck T, Guler G, Grubbs CJ, Pereira M, Zhang Z, You M, Lubet RA, Fong LY and Huebner K: CpG methylation in the Fhit regulatory region: Relation to Fhit expression in murine tumors. Oncogene. 23:3990–3998. 2004. View Article : Google Scholar : PubMed/NCBI

Kandimalla R, van Tilborg AA and Zwarthoff EC: DNA methylation-based biomarkers in bladder cancer. Nat Rev Urol. 10:327–335. 2013. View Article : Google Scholar : PubMed/NCBI

Costa VL, Henrique R, Danielsen SA, Duarte-Pereira S, Eknaes M, Skotheim RI, Rodrigues A, Magalhães JS, Oliveira J, Lothe RA, et al: Three epigenetic biomarkers, GDF15, TMEFF2, and VIM, accurately predict bladder cancer from DNA-based analyses of urine samples. Clin Cancer Res. 16:5842–5851. 2010. View Article : Google Scholar : PubMed/NCBI

Sun J, Chen Z, Zhu T, Yu J, Ma K, Zhang H, He Y, Luo X and Zhu J: Hypermethylated SFRP1, but none of other nine genes 'informative' for western countries, is valuable for bladder cancer detection in Mainland China. J Cancer Res Clin Oncol. 135:1717–1727. 2009. View Article : Google Scholar : PubMed/NCBI

Gao Q, Chen F, Zhang L, Wei A, Wang Y, Wu Z and Cao W: Inhibition of DNA methyltransferase aberrations reinstates antioxidant aging suppressors and ameliorates renal aging. Aging Cell. 21:e135262022. View Article : Google Scholar :

Li XT, Song JW, Zhang ZZ, Zhang MW, Liang LR, Miao R, Liu Y, Chen YH, Liu XY and Zhong JC: Sirtuin 7 mitigates renal ferroptosis, fibrosis and injury in hypertensive mice by facilitating the KLF15/Nrf2 signaling. Free Radic Biol Med. 193:459–473. 2022. View Article : Google Scholar : PubMed/NCBI

Zhao Y, Fan X, Wang Q, Zhen J, Li X, Zhou P, Lang Y, Sheng Q, Zhang T, Huang T, et al: ROS promote hyper-methylation of NDRG2 promoters in a DNMTS-dependent manner: Contributes to the progression of renal fibrosis. Redox Biol. 62:1026742023. View Article : Google Scholar : PubMed/NCBI

Ming S, Tian J, Ma K, Pei C, Li L, Wang Z, Fang Z, Liu M, Dong H, Li W, et al: Oxalate-induced apoptosis through ERS-ROS-NF-κB signalling pathway in renal tubular epithelial cell. Mol Med. 28:882022. View Article : Google Scholar

Doi S, Zou Y, Togao O, Pastor JV, John GB, Wang L, Shiizaki K, Gotschall R, Schiavi S, Yorioka N, et al: Klotho inhibits transforming growth factor-beta1 (TGF-beta1) signaling and suppresses renal fibrosis and cancer metastasis in mice. J Biol Chem. 286:8655–8665. 2011. View Article : Google Scholar : PubMed/NCBI

Brandt S, Bernhardt A, Häberer S, Wolters K, Gehringer F, Reichardt C, Krause A, Geffers R, Kahlfuß S, Jeron A, et al: Comparative analysis of acute kidney injury models and related fibrogenic responses: Convergence on methylation patterns regulated by cold shock protein. Cells. 13:3672024. View Article : Google Scholar : PubMed/NCBI

Miao J, Liu J, Niu J, Zhang Y, Shen W, Luo C, Liu Y, Li C, Li H, Yang P, et al: Wnt/β-catenin/RAS signaling mediates age-related renal fibrosis and is associated with mitochondrial dysfunction. Aging Cell. 18:e130042019. View Article : Google Scholar

Edeling M, Ragi G, Huang S, Pavenstadt H and Susztak K: Developmental signalling pathways in renal fibrosis: The roles of Notch, Wnt and Hedgehog. Nat Rev Nephrol. 12:426–439. 2016. View Article : Google Scholar : PubMed/NCBI

Wu J, Wei Y, Li T, Lin L, Yang Z and Ye L: DNA methylation-mediated lowly expressed AOX1 promotes cell migration and invasion of prostate cancer. Urol Int. 107:517–525. 2023. View Article : Google Scholar

Ding M, Wang Q, Zhu W, Chang J, Liao H and Xiao G: DNA methylation-mediated low expression of ZNF582 promotes the proliferation, migration, and invasion of clear cell renal cell carcinoma. Clin Exp Nephrol. 27:24–31. 2023. View Article : Google Scholar

Heichman KA and Warren JD: DNA methylation biomarkers and their utility for solid cancer diagnostics. Clin Chem Lab Med. 50:1707–1721. 2012. View Article : Google Scholar : PubMed/NCBI

Du Y, Xu Y, Guo X, Tan C, Zhu X, Liu G, Lyu X and Bei C: Methylation-regulated tumor suppressor gene PDE7B promotes HCC invasion and metastasis through the PI3K/AKT signaling pathway. BMC Cancer. 24:6242024. View Article : Google Scholar : PubMed/NCBI

Lopez-Serra P and Esteller M: DNA methylation-associated silencing of tumor-suppressor microRNAs in cancer. Oncogene. 31:1609–1622. 2012. View Article : Google Scholar :

Zhu L, Tang N, Hang H, Zhou Y, Dong J, Yang Y, Mao L, Qiu Y, Fu X and Cao W: Loss of Claudin-1 incurred by DNMT aberration promotes pancreatic cancer progression. Cancer Lett. 586:2166112024. View Article : Google Scholar : PubMed/NCBI

Lam TW, Tong JH, To KF, Chan A, Liew CT, Lai PB and Wong N: Correlative analysis of DNA methyltransferase expression and promoter hypermethylation of tumor suppressor genes in hepatocellular carcinoma. Cancer Genomics Proteomics. 3:271–277. 2006.PubMed/NCBI

Nishiyama A and Nakanishi M: Navigating the DNA methylation landscape of cancer. Trends Genet. 37:1012–1027. 2021. View Article : Google Scholar : PubMed/NCBI

O'Hagan HM, Wang W, Sen S, Destefano Shields C, Lee SS, Zhang YW, Clements EG, Cai Y, Van Neste L, Easwaran H, et al: Oxidative damage targets complexes containing DNA methyltransferases, SIRT1, and polycomb members to promoter CpG Islands. Cancer Cell. 20:606–619. 2011. View Article : Google Scholar : PubMed/NCBI

Xiao X, Chen M, Sang Y, Xue J, Jiang K, Chen Y, Zhang L, Yu S, Lv W, Li Y, et al: Methylation-mediated silencing of ATF3 promotes thyroid cancer progression by regulating prognostic genes in the MAPK and PI3K/AKT pathways. Thyroid. 33:1441–1454. 2023. View Article : Google Scholar : PubMed/NCBI

Zhu S, Xu H, Chen R, Shen Q, Yang D, Peng H, Tong J and Fu Q: DNA methylation and miR-92a-3p-mediated repression of HIP1R promotes pancreatic cancer progression by activating the PI3K/AKT pathway. J Cell Mol Med. 27:788–802. 2023. View Article : Google Scholar : PubMed/NCBI

Jin Y, Cui D, Ren J, Wang K, Zeng T and Gao L: CACNA2D3 is downregulated in gliomas and functions as a tumor suppressor. Mol Carcinog. 56:945–959. 2017. View Article : Google Scholar

Clevers H and Nusse R: Wnt/β-catenin signaling and disease. Cell. 149:1192–1205. 2012. View Article : Google Scholar : PubMed/NCBI

van Es JH, Haegebarth A, Kujala P, Itzkovitz S, Koo BK, Boj SF, Korving J, van den Born M, van Oudenaarden A, Robine S and Clevers H: A critical role for the Wnt effector Tcf4 in adult intestinal homeostatic self-renewal. Mol Cell Biol. 32:1918–1927. 2012. View Article : Google Scholar : PubMed/NCBI

Yao H, Ashihara E and Maekawa T: Targeting the Wnt/β-catenin signaling pathway in human cancers. Expert Opin Ther Targets. 15:873–887. 2011. View Article : Google Scholar : PubMed/NCBI

Yang XZ, Cheng TT, He QJ, Lei ZY, Chi J, Tang Z, Liao QX, Zhang H, Zeng LS and Cui SZ: LINC01133 as ceRNA inhibits gastric cancer progression by sponging miR-106a-3p to regulate APC expression and the Wnt/β-catenin pathway. Mol Cancer. 17:1262018. View Article : Google Scholar

Korinek V, Barker N, Morin PJ, van Wichen D, de Weger R, Kinzler KW, Vogelstein B and Clevers H: Constitutive transcriptional activation by a beta-catenin-Tcf complex in APC-/- colon carcinoma. Science. 275:1784–1787. 1997. View Article : Google Scholar : PubMed/NCBI

Nishisho I, Nakamura Y, Miyoshi Y, Miki Y, Ando H, Horii A, Koyama K, Utsunomiya J, Baba S and Hedge P: Mutations of chromosome 5q21 genes in FAP and colorectal cancer patients. Science. 253:665–669. 1991. View Article : Google Scholar : PubMed/NCBI

Yuan TL and Cantley LC: PI3K pathway alterations in cancer: Variations on a theme. Oncogene. 27:5497–5510. 2008. View Article : Google Scholar : PubMed/NCBI

Stemke-Hale K, Gonzalez-Angulo AM, Lluch A, Neve RM, Kuo WL, Davies M, Carey M, Hu Z, Guan Y, Sahin A, et al: An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer. Cancer Res. 68:6084–6091. 2008. View Article : Google Scholar : PubMed/NCBI

Jouali F, Marchoudi N, Talbi S, Bilal B, El Khasmi M, Rhaissi H and Fekkak J: Detection of PIK3/AKT pathway in Moroccan population with triple negative breast cancer. BMC Cancer. 18:9002018. View Article : Google Scholar : PubMed/NCBI

Hennessy BT, Smith DL, Ram PT, Lu Y and Mills GB: Exploiting the PI3K/AKT pathway for cancer drug discovery. Nat Rev Drug Discov. 4:988–1004. 2005. View Article : Google Scholar : PubMed/NCBI

Park JI: MAPK-ERK pathway. Int J Mol Sci. 24:96662023. View Article : Google Scholar : PubMed/NCBI

Ullah R, Yin Q, Snell AH and Wan L: RAF-MEK-ERK pathway in cancer evolution and treatment. Semin Cancer Biol. 85:123–154. 2022. View Article : Google Scholar

Gurbuz V, Sozen S, Bilen CY and Konac E: miR-148a, miR-152 and miR-200b promote prostate cancer metastasis by targeting DNMT1 and PTEN expression. Oncol Lett. 22:8052021. View Article : Google Scholar : PubMed/NCBI

Bhattacharyya S, Feferman L and Tobacman JK: Dihydrotestosterone inhibits arylsulfatase B and Dickkopf Wnt signaling pathway inhibitor (DKK)-3 leading to enhanced Wnt signaling in prostate epithelium in response to stromal Wnt3A. Prostate. 79:689–700. 2019. View Article : Google Scholar : PubMed/NCBI

Kardooni H, Gonzalez-Gualda E, Stylianakis E, Saffaran S, Waxman J and Kypta RM: CRISPR-mediated reactivation of DKK3 expression attenuates TGF-β signaling in prostate cancer. Cancers (Basel). 10:1652018. View Article : Google Scholar

Lodygin D, Epanchintsev A, Menssen A, Diebold J and Hermeking H: Functional epigenomics identifies genes frequently silenced in prostate cancer. Cancer Res. 65:4218–4227. 2005. View Article : Google Scholar : PubMed/NCBI

Bhattacharyya S, Feferman L and Tobacman JK: Chondroitin sulfatases differentially regulate Wnt signaling in prostate stem cells through effects on SHP2, phospho-ERK1/2, and Dickkopf Wnt signaling pathway inhibitor (DKK3). Oncotarget. 8:100242–100260. 2017. View Article : Google Scholar : PubMed/NCBI

Arai E, Kanai Y, Ushijima S, Fujimoto H, Mukai K and Hirohashi S: Regional DNA hypermethylation and DNA methyltransferase (DNMT) 1 protein overexpression in both renal tumors and corresponding nontumorous renal tissues. Int J Cancer. 119:288–296. 2006. View Article : Google Scholar : PubMed/NCBI

Liao F, Liao Z, Zhang T, Jiang W, Zhu P, Zhao Z, Shi H, Zhao D, Zhou N and Huang X: ECFC-derived exosomal THBS1 mediates angiogenesis and osteogenesis in distraction osteogenesis via the PI3K/AKT/ERK pathway. J Orthop Translat. 37:12–22. 2022. View Article : Google Scholar : PubMed/NCBI

Rubinek T and Wolf I: The role of alpha-Klotho as a universal tumor suppressor. Vitam Horm. 101:197–214. 2016. View Article : Google Scholar : PubMed/NCBI

Wang Y and Sun Z: Current understanding of Klotho. Ageing Res Rev. 8:43–51. 2009. View Article : Google Scholar :

Chen B, Ma X, Liu S, Zhao W and Wu J: Inhibition of lung cancer cells growth, motility and induction of apoptosis by Klotho, a novel secreted Wnt antagonist, in a dose-dependent manner. Cancer Biol Ther. 13:1221–1228. 2012. View Article : Google Scholar : PubMed/NCBI

Camilli TC, Xu M, O'Connell MP, Chien B, Frank BP, Subaran S, Indig FE, Morin PJ, Hewitt SM and Weeraratna AT: Loss of Klotho during melanoma progression leads to increased filamin cleavage, increased Wnt5A expression, and enhanced melanoma cell motility. Pigment Cell Melanoma Res. 24:175–186. 2011. View Article : Google Scholar

Li X, Lu P, Shao XF, Jiang T, Liu F and Li G: Klotho regulates epithelial-to-mesenchymal transition in vitro via Wnt/β-catenin pathway and attenuates chronic allograft dysfunction in a rat renal transplant model. Ann Transplant. 26:e9300662021. View Article : Google Scholar

Prud'homme GJ: Cancer stem cells and novel targets for antitumor strategies. Curr Pharm Des. 18:2838–2849. 2012. View Article : Google Scholar : PubMed/NCBI

Costa VL, Henrique R, Ribeiro FR, Carvalho JR, Oliveira J, Lobo F, Teixeira MR and Jerónimo C: Epigenetic regulation of Wnt signaling pathway in urological cancer. Epigenetics. 5:343–351. 2010. View Article : Google Scholar : PubMed/NCBI

Henrique R, Ribeiro FR, Fonseca D, Hoque MO, Carvalho AL, Costa VL, Pinto M, Oliveira J, Teixeira MR, Sidransky D and Jerónimo C: High promoter methylation levels of APC predict poor prognosis in sextant biopsies from prostate cancer patients. Clin Cancer Res. 13:6122–6129. 2007. View Article : Google Scholar : PubMed/NCBI

Rogler A, Kendziorra E, Giedl J, Stoehr C, Taubert H, Goebell PJ, Wullich B, Stöckle M, Lehmann J, Petsch S, et al: Functional analyses and prognostic significance of SFRP1 expression in bladder cancer. J Cancer Res Clin Oncol. 141:1779–1790. 2015. View Article : Google Scholar : PubMed/NCBI

Robertson KD and Jones PA: DNA methylation: Past, present and future directions. Carcinogenesis. 21:461–467. 2000. View Article : Google Scholar : PubMed/NCBI

Myöhänen SK, Baylin SB and Herman JG: Hypermethylation can selectively silence individual p16ink4A alleles in neoplasia. Cancer Res. 58:591–593. 1998.PubMed/NCBI

Kucuk O: Cancer biomarkers. Mol Aspects Med. 45:1–2. 2015. View Article : Google Scholar : PubMed/NCBI

O'Reilly E, Tuzova AV, Walsh AL, Russell NM, O'Brien O, Kelly S, Dhomhnallain ON, DeBarra L, Dale CM, Brugman R, et al: epiCaPture: A urine DNA methylation test for early detection of aggressive prostate cancer. JCO Precis Oncol. 2019:PO.18.001342019.PubMed/NCBI

Mikeska T and Craig JM: DNA methylation biomarkers: Cancer and beyond. Genes (Basel). 5:821–864. 2014. View Article : Google Scholar : PubMed/NCBI

Mahon KL, Qu W, Devaney J, Paul C, Castillo L, Wykes RJ, Chatfield MD, Boyer MJ, Stockler MR, Marx G, et al: Methylated glutathione S-transferase 1 (mGSTP1) is a potential plasma free DNA epigenetic marker of prognosis and response to chemotherapy in castrate-resistant prostate cancer. Br J Cancer. 111:1802–1809. 2014. View Article : Google Scholar : PubMed/NCBI

Ibrahim J, Peeters M, Van Camp G and Opde Beeck K: Methylation biomarkers for early cancer detection and diagnosis: Current and future perspectives. Eur J Cancer. 178:91–113. 2023. View Article : Google Scholar

Waterhouse RL Jr, Van Neste L, Moses KA, Barnswell C, Silberstein JL, Jalkut M, Tutrone R, Sylora J, Anglade R, Murdock M, et al: Evaluation of an epigenetic assay for predicting repeat prostate biopsy outcome in African American men. Urology. 128:62–65. 2019. View Article : Google Scholar

Yamagishi M, Kuze Y, Kobayashi S, Nakashima M, Morishima S, Kawamata T, Makiyama J, Suzuki K, Seki M, Abe K, et al: Mechanisms of action and resistance in histone methylation-targeted therapy. Nature. 627:221–228. 2024. View Article : Google Scholar : PubMed/NCBI

Sgro A, Cursons J, Waryah C, Woodward EA, Foroutan M, Lyu R, Yeoh GCT, Leedman PJ and Blancafort P: Epigenetic reactivation of tumor suppressor genes with CRISPRa technologies as precision therapy for hepatocellular carcinoma. Clin Epigenetics. 15:732023. View Article : Google Scholar : PubMed/NCBI

Patra A, Deb M, Dahiya R and Patra SK: 5-Aza-2′-deoxycytidine stress response and apoptosis in prostate cancer. Clin Epigenetics. 2:339–348. 2011. View Article : Google Scholar

Issa JP: Decitabine. Curr Opin Oncol. 15:446–451. 2003. View Article : Google Scholar : PubMed/NCBI

Graça I, Sousa EJ, Baptista T, Almeida M, Ramalho-Carvalho J, Palmeira C, Henrique R and Jerónimo C: Anti-tumoral effect of the non-nucleoside DNMT inhibitor RG108 in human prostate cancer cells. Curr Pharm Des. 20:1803–1811. 2014. View Article : Google Scholar

Wang C, Lei L, Xu Y, Li Y, Zhang J, Xu Y and Si S: Trichostatin C synergistically interacts with DNMT inhibitor to induce antineoplastic effect via inhibition of axl in bladder and lung cancer cells. Pharmaceuticals (Basel). 17:4252024. View Article : Google Scholar : PubMed/NCBI

Laranjeira ABA, Hollingshead MG, Nguyen D, Kinders RJ, Doroshow JH and Yang SX: DNA damage, demethylation and anticancer activity of DNA methyltransferase (DNMT) inhibitors. Sci Rep. 13:59642023. View Article : Google Scholar : PubMed/NCBI

Kim SJ, Cheresh P, Eren M, Jablonski RP, Yeldandi A, Ridge KM, Budinger GRS, Kim DH, Wolf M, Vaughan DE and Kamp DW: Klotho, an antiaging molecule, attenuates oxidant-induced alveolar epithelial cell mtDNA damage and apoptosis. Am J Physiol Lung Cell Mol Physiol. 313:L16–L26. 2017. View Article : Google Scholar : PubMed/NCBI

Yamada Y, Venkadakrishnan VB, Mizuno K, Bakht M, Ku SY, Garcia MM and Beltran H: Targeting DNA methylation and B7-H3 in RB1-deficient and neuroendocrine prostate cancer. Sci Transl Med. 15:eadf67322023. View Article : Google Scholar : PubMed/NCBI

Tikoo K, Ali IY, Gupta J and Gupta C: 5-Azacytidine prevents cisplatin induced nephrotoxicity and potentiates anticancer activity of cisplatin by involving inhibition of metallothionein, pAKT and DNMT1 expression in chemical induced cancer rats. Toxicol Lett. 191:158–166. 2009. View Article : Google Scholar : PubMed/NCBI

Hosokawa O, Okabe M, Saito S, Saito T and Kurasaki M: Protective role of metallothionein on DNA damage in rat kidney caused by cis-diamminedichloroplatinum. Pharmacol Toxicol. 86:276–282. 2000. View Article : Google Scholar : PubMed/NCBI

Francia G, Green SK, Bocci G, Man S, Emmenegger U, Ebos JM, Weinerman A, Shaked Y and Kerbel RS: Down-regulation of DNA mismatch repair proteins in human and murine tumor spheroids: Implications for multicellular resistance to alkylating agents. Mol Cancer Ther. 4:1484–1494. 2005. View Article : Google Scholar : PubMed/NCBI

Plumb JA, Strathdee G, Sludden J, Kaye SB and Brown R: Reversal of drug resistance in human tumor xenografts by 2′-deoxy-5-azacytidine-induced demethylation of the hMLH1 gene promoter. Cancer Res. 60:6039–6044. 2000.PubMed/NCBI

Dai X, Ren T, Zhang Y and Nan N: Methylation multiplicity and its clinical values in cancer. Expert Rev Mol Med. 23:e22021. View Article : Google Scholar : PubMed/NCBI

Ricketts CJ, Hill VK and Linehan WM: Tumor-specific hypermethylation of epigenetic biomarkers, including SFRP1, predicts for poorer survival in patients from the TCGA kidney renal clear cell carcinoma (KIRC) project. PLoS One. 9:e856212014. View Article : Google Scholar : PubMed/NCBI

Peters I, Dubrowinskaja N, Abbas M, Seidel C, Kogosov M, Scherer R, Gebauer K, Merseburger AS, Kuczyk MA, Grünwald V and Serth J: DNA methylation biomarkers predict progression-free and overall survival of metastatic renal cell cancer (mRCC) treated with antiangiogenic therapies. PLoS One. 9:e914402014. View Article : Google Scholar : PubMed/NCBI

Dubrowinskaja N, Gebauer K, Peters I, Hennenlotter J, Abbas M, Scherer R, Tezval H, Merseburger AS, Stenzl A, Grünwald V, et al: Neurofilament heavy polypeptide CpG island methylation associates with prognosis of renal cell carcinoma and prediction of antivascular endothelial growth factor therapy response. Cancer Med. 3:300–309. 2014. View Article : Google Scholar : PubMed/NCBI

Lou W, Krill D, Dhir R, Becich MJ, Dong JT, Frierson HF Jr, Isaacs WB, Isaacs JT and Gao AC: Methylation of the CD44 metastasis suppressor gene in human prostate cancer. Cancer Res. 59:2329–2331. 1999.PubMed/NCBI

Kito H, Suzuki H, Ichikawa T, Sekita N, Kamiya N, Akakura K, Igarashi T, Nakayama T, Watanabe M, Harigaya K and Ito H: Hypermethylation of the CD44 gene is associated with progression and metastasis of human prostate cancer. Prostate. 49:110–115. 2001. View Article : Google Scholar : PubMed/NCBI

Yegnasubramanian S, Kowalski J, Gonzalgo ML, Zahurak M, Piantadosi S, Walsh PC, Bova GS, De Marzo AM, Isaacs WB and Nelson WG: Hypermethylation of CpG islands in primary and metastatic human prostate cancer. Cancer Res. 64:1975–1986. 2004. View Article : Google Scholar : PubMed/NCBI

Pan Y, Liu G, Zhou F, Su B and Li Y: DNA methylation profiles in cancer diagnosis and therapeutics. Clin Exp Med. 18:1–14. 2018. View Article : Google Scholar

Altucci L and Rots MG: Epigenetic drugs: From chemistry via biology to medicine and back. Clin Epigenetics. 8:562016. View Article : Google Scholar : PubMed/NCBI

Egger G, Liang G, Aparicio A and Jones PA: Epigenetics in human disease and prospects for epigenetic therapy. Nature. 429:457–463. 2004. View Article : Google Scholar : PubMed/NCBI

Cossio FP, Esteller M and Berdasco M: Towards a more precise therapy in cancer: Exploring epigenetic complexity. Curr Opin Chem Biol. 57:41–49. 2020. View Article : Google Scholar : PubMed/NCBI

Kondrashov A and Karpova E: Notes on functional modules in the assembly of CRISPR/Cas9-mediated epigenetic modifiers. Methods Mol Biol. 2198:401–428. 2021. View Article : Google Scholar

Liang F, Dong Z, Ye J, Hu W, Bhandari RK, Mai K and Wang X: In vivo DNA methylation editing in zebrafish. Epigenetics. 18:21923262023. View Article : Google Scholar : PubMed/NCBI